WO2004078104A3 - Pyridylsulfonamido pyrimidines for treating diabetic nephropathy - Google Patents

Pyridylsulfonamido pyrimidines for treating diabetic nephropathy Download PDF

Info

Publication number
WO2004078104A3
WO2004078104A3 PCT/EP2004/050242 EP2004050242W WO2004078104A3 WO 2004078104 A3 WO2004078104 A3 WO 2004078104A3 EP 2004050242 W EP2004050242 W EP 2004050242W WO 2004078104 A3 WO2004078104 A3 WO 2004078104A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetic nephropathy
pyridylsulfonamido
pyrimidines
treating diabetic
zero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/050242
Other languages
French (fr)
Other versions
WO2004078104A2 (en
Inventor
Jessica Mann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Speedel Development AG
Original Assignee
Speedel Development AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE602004013734T priority Critical patent/DE602004013734D1/en
Priority to MXPA05009478A priority patent/MXPA05009478A/en
Priority to YUP-2005/0683A priority patent/RS20050683A/en
Priority to PL04716605T priority patent/PL1601361T3/en
Priority to JP2006505443A priority patent/JP4737686B2/en
Priority to UAA200509348A priority patent/UA82087C2/en
Priority to BRPI0408082-3A priority patent/BRPI0408082A/en
Priority to ES04716605T priority patent/ES2305737T3/en
Priority to HR20050860A priority patent/HRP20050860A2/en
Priority to NZ542155A priority patent/NZ542155A/en
Priority to US10/548,080 priority patent/US20060094731A1/en
Priority to CA2517930A priority patent/CA2517930C/en
Priority to KR1020057016511A priority patent/KR101099189B1/en
Application filed by Speedel Development AG filed Critical Speedel Development AG
Priority to SI200430798T priority patent/SI1601361T1/en
Priority to HK06103985.5A priority patent/HK1083761B/en
Priority to DK04716605T priority patent/DK1601361T3/en
Priority to AU2004216858A priority patent/AU2004216858B2/en
Priority to EP04716605A priority patent/EP1601361B1/en
Publication of WO2004078104A2 publication Critical patent/WO2004078104A2/en
Publication of WO2004078104A3 publication Critical patent/WO2004078104A3/en
Priority to IL170626A priority patent/IL170626A/en
Priority to NO20054148A priority patent/NO20054148L/en
Anticipated expiration legal-status Critical
Priority to US12/219,751 priority patent/US20090005404A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

The present invention relates to the use of a compound of formula (I) wherein R1 is pyridyl or thiazolyl, any of which may optionally be substituted with C1-8alkyl or C2-8alkenyl; and a) R2 is methoxy and n is zero or one; or b) R2 is chlorine and n is zero and pharmaceutically acceptable salts thereof for lowering or controlling proteinuria, in particular for the treatment of diabetic nephropathy.
PCT/EP2004/050242 2003-03-06 2004-03-03 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy Ceased WO2004078104A2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
KR1020057016511A KR101099189B1 (en) 2003-03-06 2004-03-03 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
YUP-2005/0683A RS20050683A (en) 2003-03-06 2004-03-03 New medicament
PL04716605T PL1601361T3 (en) 2003-03-06 2004-03-03 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
JP2006505443A JP4737686B2 (en) 2003-03-06 2004-03-03 New medicine
UAA200509348A UA82087C2 (en) 2003-03-06 2004-03-03 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
BRPI0408082-3A BRPI0408082A (en) 2003-03-06 2004-03-03 medicine
ES04716605T ES2305737T3 (en) 2003-03-06 2004-03-03 PIRIDILSULFONAMIDOPIRIMIDINAS FOR THE TREATMENT OF DIABETIC NEFROPATIA.
HR20050860A HRP20050860A2 (en) 2003-03-06 2004-03-03 New medicament
MXPA05009478A MXPA05009478A (en) 2003-03-06 2004-03-03 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy.
US10/548,080 US20060094731A1 (en) 2003-03-06 2004-03-03 New medicament
CA2517930A CA2517930C (en) 2003-03-06 2004-03-03 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
DE602004013734T DE602004013734D1 (en) 2003-03-06 2004-03-03 PYRIDLSULFONAMIDOPYRIMIDINE FOR THE TREATMENT OF DIABETIC NEPHROPATHY
NZ542155A NZ542155A (en) 2003-03-06 2004-03-03 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
EP04716605A EP1601361B1 (en) 2003-03-06 2004-03-03 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
HK06103985.5A HK1083761B (en) 2003-03-06 2004-03-03 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
DK04716605T DK1601361T3 (en) 2003-03-06 2004-03-03 Pyridylsulfonamidopyrimidines for the treatment of iabetic nephropathy
AU2004216858A AU2004216858B2 (en) 2003-03-06 2004-03-03 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
SI200430798T SI1601361T1 (en) 2003-03-06 2004-03-03 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
IL170626A IL170626A (en) 2003-03-06 2005-09-01 Pyridylsulfonamido pyrimidines for use in treating diabetic nephropathy
NO20054148A NO20054148L (en) 2003-03-06 2005-09-06 New drug
US12/219,751 US20090005404A1 (en) 2003-03-06 2008-07-28 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03100549.9 2003-03-06
EP03100549A EP1454625A1 (en) 2003-03-06 2003-03-06 Pyridylsulfonamidyl-pyrimidines for the treatment of diabetic nephropathies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/219,751 Division US20090005404A1 (en) 2003-03-06 2008-07-28 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy

Publications (2)

Publication Number Publication Date
WO2004078104A2 WO2004078104A2 (en) 2004-09-16
WO2004078104A3 true WO2004078104A3 (en) 2004-10-28

Family

ID=32799012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/050242 Ceased WO2004078104A2 (en) 2003-03-06 2004-03-03 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy

Country Status (26)

Country Link
US (2) US20060094731A1 (en)
EP (2) EP1454625A1 (en)
JP (1) JP4737686B2 (en)
KR (1) KR101099189B1 (en)
CN (1) CN100453081C (en)
AT (1) ATE395063T1 (en)
AU (2) AU2004216858B2 (en)
BR (1) BRPI0408082A (en)
CA (1) CA2517930C (en)
CY (1) CY1108241T1 (en)
DE (1) DE602004013734D1 (en)
DK (1) DK1601361T3 (en)
EC (1) ECSP056060A (en)
ES (1) ES2305737T3 (en)
HR (1) HRP20050860A2 (en)
IL (1) IL170626A (en)
MX (1) MXPA05009478A (en)
NO (1) NO20054148L (en)
NZ (1) NZ542155A (en)
PL (1) PL1601361T3 (en)
PT (1) PT1601361E (en)
RS (1) RS20050683A (en)
SI (1) SI1601361T1 (en)
UA (1) UA82087C2 (en)
WO (1) WO2004078104A2 (en)
ZA (1) ZA200507122B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1595880A1 (en) * 2004-05-13 2005-11-16 Speedel Pharma AG Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists
JP2009507890A (en) * 2005-09-12 2009-02-26 シュペーデル・ファルマ・アーゲー Pyridylsulfonamidyl-pyrimidines for the prevention of vascular graft dysfunction
CN102933233A (en) 2010-06-17 2013-02-13 日东电工株式会社 Agent for treating renal fibrosis
CN109260164A (en) * 2018-10-07 2019-01-25 威海贯标信息科技有限公司 A kind of avosentan tablet composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081335A1 (en) * 2000-04-20 2001-11-01 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
US6417360B1 (en) * 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0750500A1 (en) * 1994-03-17 1997-01-02 Ciba-Geigy Ag Treatment of diabetic nephropathy with valsartan
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
EP0841926B1 (en) * 1995-08-02 2003-03-26 Smithkline Beecham Corporation Endothelin receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417360B1 (en) * 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides
WO2001081335A1 (en) * 2000-04-20 2001-11-01 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BENIGNI A; COLOSIO V; BRENA C; BRUZZI I; BERTANI T; REMUZZI G: "Unselective Inhibition of Endothelin Receptors Reduces Renal Dysfunction in Experimental Diabetes", DIABETES, vol. 47, no. 3, 1 March 1998 (1998-03-01), pages 450 - 456, XP001180574 *
SUGIMOTO KOH-ICHI; TSURUOKA SHUICHI; FUJIMURA AKIO: "Renal protective effect of YM598, a selective endothelin ET(A) receptor antagonist, against diabetic nephropathy in OLETF rats.", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 450, no. 2, 23 August 2002 (2002-08-23), NETHERLANDS, pages 183 - 189, XP002288658 *

Also Published As

Publication number Publication date
ATE395063T1 (en) 2008-05-15
CA2517930C (en) 2011-04-26
CN1756552A (en) 2006-04-05
ECSP056060A (en) 2006-01-27
AU2004216858B2 (en) 2009-07-16
PL1601361T3 (en) 2008-10-31
CA2517930A1 (en) 2004-09-16
HRP20050860A2 (en) 2005-10-31
NO20054148L (en) 2005-09-06
CN100453081C (en) 2009-01-21
AU2009225323B2 (en) 2011-11-24
UA82087C2 (en) 2008-03-11
AU2009225323A1 (en) 2009-11-05
KR20050106083A (en) 2005-11-08
SI1601361T1 (en) 2008-10-31
US20060094731A1 (en) 2006-05-04
DK1601361T3 (en) 2008-08-25
NZ542155A (en) 2008-09-26
US20090005404A1 (en) 2009-01-01
AU2004216858A1 (en) 2004-09-16
EP1601361B1 (en) 2008-05-14
ZA200507122B (en) 2006-05-31
JP2006519817A (en) 2006-08-31
JP4737686B2 (en) 2011-08-03
EP1601361A2 (en) 2005-12-07
CY1108241T1 (en) 2013-09-04
IL170626A (en) 2010-05-31
PT1601361E (en) 2008-07-29
ES2305737T3 (en) 2008-11-01
EP1454625A1 (en) 2004-09-08
DE602004013734D1 (en) 2008-06-26
MXPA05009478A (en) 2005-10-18
WO2004078104A2 (en) 2004-09-16
KR101099189B1 (en) 2011-12-27
RS20050683A (en) 2007-11-15
HK1083761A1 (en) 2006-07-14
BRPI0408082A (en) 2006-02-14

Similar Documents

Publication Publication Date Title
WO2008011453A3 (en) SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1
NO20052796L (en) Indolylpyrazinone derivatives useful for the treatment of hyperproliferative disorders and disorders associated with angiogenesis
NO20051103L (en) Indole-3-carboxamides as Glucokinase (GK) Activators
WO2004022537A3 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
SI1940786T1 (en) Biphenyl derivatives and their use in treating hepatitis c
NZ594385A (en) Aminopyrimidines useful as kinase inhibitors
GB0226930D0 (en) Chemical compounds
ATE453393T1 (en) USE OF PYRIDYLAMIDE AS ANGIOGENESIS INHIBITORS
TW200505919A (en) DPP-IV inhibitors
BR0314059A (en) Heterocyclic compounds
DK1474395T3 (en) Nicotinamide derivatives useful as p38 inhibitors
TW200732331A (en) Fused heterocyclic compound and use thereof
WO2005066139A3 (en) 2-(amino-substituted)-4-aryl pyramidines and related compounds useful for treating inflammatory diseases
CA2474510A1 (en) Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
WO2006058628A3 (en) Substituted benzoquinolizines as dpp-iv inhibitors for the treatment of diabetes
NO20070974L (en) Substituted N-acyl-2-aminothiazoles
GB0412314D0 (en) Compounds
PL370322A1 (en) 2-amino-4-heteroarylethyl thiazoline derivatives and their use an inhibitors of inducible no-synthase
MXPA05009478A (en) Pyridylsulfonamido pyrimidines for treating diabetic nephropathy.
ATE297902T1 (en) SULFONYL PYRIDAZINONE DERIVATIVES FOR USE AS ALDOSE REDUCTASE INHIBITORS
WO2008155081A3 (en) Substituted aromatic heterocyclic compounds as fungicides
WO2007024600A3 (en) Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof
WO2005075456A8 (en) 2-(piperidin-4-yl) -4, 5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
TW200519071A (en) 3-aryl-2-cyano-3-hydroxy-acrylic acid derivatives
WO2007051133A3 (en) Substituted thiazoles and their use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200501324

Country of ref document: VN

Ref document number: P-2005/0683

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1-2005-501607

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 170626

Country of ref document: IL

Ref document number: 542155

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2517930

Country of ref document: CA

Ref document number: 20048058469

Country of ref document: CN

Ref document number: 3938/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004716605

Country of ref document: EP

Ref document number: 2005/07122

Country of ref document: ZA

Ref document number: 2004216858

Country of ref document: AU

Ref document number: 1020057016511

Country of ref document: KR

Ref document number: 200507122

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2006094731

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/009478

Country of ref document: MX

Ref document number: 2006505443

Country of ref document: JP

Ref document number: 10548080

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 05093524

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: P20050860A

Country of ref document: HR

ENP Entry into the national phase

Ref document number: 2004216858

Country of ref document: AU

Date of ref document: 20040303

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004216858

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20050355

Country of ref document: UZ

WWP Wipo information: published in national office

Ref document number: 1020057016511

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004716605

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0408082

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10548080

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2004716605

Country of ref document: EP